2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework

A. Leuzy, N. J. Ashton, N. Mattsson-Carlgren, A. Dodich, M. Boccardi, J. Corre, A. Drzezga, A. Nordberg, R. Ossenkoppele, H. Zetterberg, K. Blennow, G. B. Frisoni, V. Garibotto, O. Hansson

Research output: Contribution to journalReview articlepeer-review

10 Citations (SciVal)

Fingerprint

Dive into the research topics of '2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework'. Together they form a unique fingerprint.

Medicine & Life Sciences